Aclaris Therapeutics to Attend Upcoming Investor Conferences
November 02 2018 - 4:01PM
Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a dermatologist-led
biopharmaceutical company committed to identifying, developing, and
commercializing innovative therapies to address significant unmet
needs in aesthetic and medical dermatology and immunology, today
announced that management will attend the following conferences:
- Dr. Neal Walker, President and Chief Executive Officer, will
present at the Credit Suisse 27th Annual Healthcare Conference in
Scottsdale, AZ on Thursday, November 15, 2018 at 8:00 AM MST.
Management will also host investor meetings on Thursday, November
15, 2018.
- Dr. Neal Walker, President and Chief Executive Officer, will
present at the Evercore ISI Healthcare Conference in Boston, MA on
Tuesday, November 27, 2018 at 3:05 PM EST. Management will also
host investor meetings on Tuesday, November 27, 2018.
- Dr. Neal Walker, President and Chief Executive Officer, will
present at the 30th Annual Piper Jaffray Healthcare Conference in
New York, NY on Wednesday, November 28, 2018 at 3:30 PM EST.
Management will also host investor meetings on Wednesday, November
28, 2018.
A live webcast of the Credit Suisse 27th Annual Healthcare
Conference, Evercore ISI Healthcare Conference, and the 30th Annual
Piper Jaffray Healthcare Conference presentations may be accessed
through the Company's web site, www.aclaristx.com, on the 'Events
and Presentations' section. An archived version of the presentation
will be available for 30 days.
About Aclaris Therapeutics, Inc.
Aclaris Therapeutics, Inc. is a dermatologist-led
biopharmaceutical company focused on identifying, developing, and
commercializing innovative therapies to address significant unmet
needs in aesthetic and medical dermatology, and immunology.
Aclaris’ focus on market segments with no FDA-approved medications
or where treatment gaps exist has resulted in the first
FDA-approved treatment for raised seborrheic keratoses and several
clinical programs to develop medications for the potential
treatment of common warts, alopecia areata, and vitiligo. For
additional information, please visit www.aclaristx.com and follow
Aclaris on LinkedIn.
Contact:
Aclaris ContactMichael Tung, M.D.Senior Vice President Corporate
Strategy/Investor Relations484-329-2140mtung@aclaristx.com
Media ContactSheila KennedyVice President, Corporate
Communications484-321-5559media@aclaristx.com
Aclaris Therapeutics (NASDAQ:ACRS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Aclaris Therapeutics (NASDAQ:ACRS)
Historical Stock Chart
From Jul 2023 to Jul 2024